In a recent piece for the Daily Caller, Charles Sauer highlights a growing disconnect between medical innovation and public policy when it comes to Alzheimer’s care—and the consequences could not be more serious.
Health and Human Services Secretary Robert F. Kennedy Jr. recently put it plainly: “it is regulatory malpractice that we don’t have early [Alzheimer’s] screening already,” noting that early treatment can postpone the onset of the disease.
That observation underscores a broader issue. For decades, Alzheimer’s policy has been built around late-stage, crisis-driven care. By the time patients receive meaningful intervention, the disease has often progressed too far for treatment to have its full effect. This approach isn’t just medically outdated—it’s economically unsustainable.
As Sauer explains, “Alzheimer’s policy has been built around costly late-stage crisis care instead of early diagnosis and action, which can extend healthy lives and prevent or postpone costly long-term care.”
The scale of the challenge is immense. More than 7 million Americans are currently living with Alzheimer’s, a number expected to nearly double by 2060. At the same time, the average cost of a semi-private nursing home room exceeds $112,000 per year, placing increasing strain on families and federal programs alike. Medicare’s hospital insurance trust fund is projected to be depleted by 2033, raising further concerns about long-term sustainability.
But there is reason for optimism—if policymakers are willing to act.
Advances in diagnostics and treatment are changing what is possible. New tools, including blood-based tests, can now identify Alzheimer’s risk years before symptoms fully emerge. As Centers for Medicare & Medicaid Services Administrator Mehmet Oz has noted, these innovations open the door to earlier and more effective intervention.
And early intervention works.
Patients who act during the early stages of the disease can delay cognitive decline, extend their independence, and reduce the need for costly long-term care. In some cases, treatment can help patients maintain their routines and quality of life for years longer than previously expected.
The economic implications are just as compelling.
Extending healthy life expectancy by just one year is estimated to be worth roughly $566,000 per person. More broadly, investments in early detection and prevention could save the U.S. healthcare system up to $2.2 trillion annually by 2040.
Yet despite these advances, policy continues to lag behind.
Regulatory barriers and slow adoption of new technologies prevent patients from accessing these tools when they are most effective. In a disease where timing is critical, these delays carry real consequences.
That is why Sauer points to policy solutions like the ASAP Act, which would help integrate FDA-approved diagnostic tools into routine screening and make early detection more accessible. Creating clearer, more predictable pathways for innovation would also ensure that new treatments reach patients without unnecessary delay.
Importantly, these reforms are widely supported. Polling shows overwhelming bipartisan agreement that prevention and early detection can reduce costs and improve outcomes. Voters recognize what policymakers must now confront: waiting until Alzheimer’s reaches its most severe stages is both the most expensive and least effective approach.
The bottom line is clear. The science has advanced, but the system has not.
As Sauer’s piece makes evident, the tools to change the trajectory of Alzheimer’s disease already exist. Aligning policy with innovation will not only improve patient outcomes—it will also help avert a looming fiscal crisis.
We know what works. Now it’s time for policymakers to catch up.
Read the full piece at Daily Caller by clicking here.
